ClinicalTrials.gg
Status unknownNCT05576753PUMAUpdated Mar 22, 2023

Preperitoneal Umbilical Mesh Area

An interventional study of Hernia repair in Ventral Hernia, Umbilical Hernia and Ventral Incisional Hernia, sponsored by Algemeen Ziekenhuis Maria Middelares. Status unknown at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-22.

Primary conditionHernia, UmbilicalRegistry: Hernia, VentralReclassifiedWhy we changed it
Registry
Hernia, Ventral — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hernia, Umbilical
Why
  1. The study's listed conditions name Hernia, Umbilical, a narrower term within Hernia, Ventral.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Algemeen Ziekenhuis Maria Middelares · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to measure the mesh shrinkage and the visualization of the mesh with MRI scan at 1 month and 13 months after robot assisted preperitoneal hernia repair using the visible CICAT mesh (Dynamesh®).

Read the detailed description

The study will be conducted in the department of surgery in het AZ Maria Middelares, Ghent, Belgium. Dr. Filip Muysoms will personally select and operate all patients eligible for this study. He will inform all patients about the surgery and the follow-up with MRI scan thereafter. Dr. Beckers will perform all MRI examinations of the patients at 1 month and 13 months post-operatively and will be available for questions from the patient.

We want to show that with this type of mesh it is possible to visualize the preperitoneal placed mesh in a safe manner. Furthermore, the positioning of the mesh, mesh shrinkage or mesh shifting will be monitored with this technique. This provides long-term benefit and provides early treatment possibilities in case of post-operative complications related to the mesh position.

02

Conditions studied

  • Ventral Hernia
  • Umbilical Hernia
  • Ventral Incisional Hernia

Browse trials for

Keywords

  • Mesh shrinkage
  • Abdominal wall surgery
03

In context

Hernia, Umbilical Reclassified

67 studies on the registry are indexed under Hernia, Umbilical; 13 are open to participants now.

This study's planned enrollment of 20 is below the median of 66 across 40 interventional studies indexed under Hernia, Umbilical.

Browse Hernia, Umbilical studies →

Lead sponsor

Algemeen Ziekenhuis Maria Middelares is the lead sponsor of 37 studies on the registry; 8 are open to participants now.

Compared within Hernia, Umbilical, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hernia, Ventral. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary umbilical hernias up to 2 cm
  • Incisional hernias limited to zone M3 (EHS classification) and smaller than 2 cm

Exclusion criteria

Exclusion Criteria:

  • \<18 years
  • Emergency surgery (incarcerated hernia)
  • Clean-contaminated, contaminated or dirty procedures (according to the CDC classification)
  • Lateral hernias
  • Hernias close to the sternum or the pubic bone
  • Hernias bigger than 2 cm in diameter.
  • Hernias that need a component separation technique.
  • Previous mesh repair on the midline
  • > 4
  • Pregnancy
  • No patient
  • of less than 2years
  • for MRI
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Patient

    Patients scheduled for robot assisted laparoscopic preperitoneal repair (vTAPP: ventral transabdominal preperitoneal hernia repair) of a midline ventral hernia

    Procedure: Hernia repair

Interventions

  • ProcedureHernia repair

    Robot assisted laparoscopic preperitoneal repair (vTAPP: ventral transabdominal preperitoneal hernia repair) of a midline ventral hernia

06

What researchers measure

Primary outcomes

  1. Change of mesh surface (percentage)

    Shrinkage rate / change of the mesh surface (percentage) as measured with the MRI between 1 month and 13 months postoperatively, defined as (100 - mesh surface at 13 months x 100 / mesh surface at 1 month)

    Time frame: 1 month and 13 month post-operatively

Secondary outcomes

  1. Change in mesh surface between implantation surface size

    Change in mesh surface between implantation surface size, surface at 1m and at 13m

    Time frame: 1 month and 13 month post-operatively

  2. Change in mesh width and length between implantation surface size

    Change in mesh width and length between implantation surface size, surface at 1m and at 13m

    Time frame: 1 month and 13 month post-operatively

  3. Operation duration

    Recording of the operation duration needed for robot-assisted ventral TAPP procedure

    Time frame: once during operation

  4. Intra-operative complications

    Intra-operative complications registered until 4 weeks after the hernia repair

    Time frame: until 4 weeks post-operative

  5. Early post-operative complications

    Early post-operative complications detected until 30 days after hernia repair

    Time frame: until 30 days post-operative

  6. Late complications

    Late complications (after 30 days)

    Time frame: After 30 days post-operative

  7. Quality of Life questionnaire

    Minimum score is 0, maximum score is 90. The higher the score, the worse the outcome

    Time frame: Preoperatively, 30 days, 13 months

  8. Body image score

    Minimum score is 0, maximum score is 10. A higher score means a higher level of body image disturbance (worse outcome).

    Time frame: Preoperatively, 30 days, 13 months

07

Study locations

1 of 1 sites recruiting
  • AZ Maria Middelares
    Ghent, 9000, Belgium
    Recruiting
    • Maaike Vierstraete, MD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2023, 10 months after the start.

Of 19 interventional studies with no phase under Hernia, Umbilical, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 47. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2022
First posted
Oct 12, 2022
StartActual
Feb 1, 2023
Primary completionEst.
Dec 31, 2023
CompletionEst.
Apr 1, 2025
Last update
Mar 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05576753
Lead sponsor
Algemeen Ziekenhuis Maria Middelares
Responsible party
Maaike Vierstraete (Medical Doctor Department General Surgery, Algemeen Ziekenhuis Maria Middelares) — Principal investigator
First posted
Oct 12, 2022
Start date
Feb 1, 2023
Primary completion
Dec 31, 2023 (estimated)
Completion
Apr 1, 2025 (estimated)
Last update
Mar 22, 2023

Study contacts

Maaike Vierstraete, MD
Contact
maaikevierstraete@icloud.com
003292467400
Filip Muysoms, MD
Contact
filip.muysoms@azmmsj.be
003282467400
Maaike Vierstraete
principal investigator · Algemeen Ziekenhuis Maria Middelares

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion